Cellphire Therapeutics is developing next generation allogeneic cellular therapeutics that harness the inherent biological capabilities of human cells. Our therapeutic platform consists of three technological capabilities:
Our lead product, Thrombosomes®, currently in Phase 2 clinical trials, is the starting point on the way to achieving our Vision. The technologies developed while creating Thrombosomes® enable a host of novel cellular therapies previously not possible.
About our scienceCellphire is actively recruiting study sites for two Phase 2 clinical trials.
We are continually exploring new applications for stabilized cellular therapies.